NCT07624838招募中不适用
Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea37 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年2月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 37
研究概览
简要总结
The goal of this observational study is to evaluate how well brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (CHP) works and how safe it is when used as first-line treatment in adults with CD30-positive peripheral T-cell lymphoma in Spain during routine clinical care.
The main questions this study aims to answer are:
- How long do participants live without their lymphoma getting worse after starting treatment?
- How well does this treatment reduce or eliminate the lymphoma?
- How long do participants live after receiving this treatment?
- What side effects do participants experience, including nerve problems and low white blood cell counts?
Participants have already received brentuximab vedotin plus CHP as part of their usual medical care. Researchers will collect information from existing medical records to better understand treatment outcomes and safety in real-world clinical practice across multiple centers in Spain.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of CD30-positive peripheral T-cell lymphoma, including anaplastic large cell lymphoma (ALK-positive, ALK-negative, breast implant-associated), peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma.
- •Patients 18 years of age or older at the time of treatment with BV-CHP.
- •Patients treated with brentuximab vedotin plus CHP as first-line therapy between January 2019 and September 2024
排除标准
- •Patients who have received prior treatment for their lymphoma
- •Patients who have received the combination as part of a clinical trial.
研究者
研究点 (37)
Loading locations...
相似试验
招募中
3 期
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCNCT07459296First Affiliated Hospital of Guangxi Medical University266
尚未招募
1 期
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic LeukemiaNCT07283640M.D. Anderson Cancer Center20
尚未招募
3 期
Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCCSquamous Cell Carcinoma of Head and NeckNCT07509099Ji Dongmei316
招募中
3 期
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)Urothelial CancerUrinary Bladder NeoplasmsNCT07566156Astellas Pharma Global Development, Inc.390
尚未招募
2 期
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT07557056Jennifer Woyach25